Presentations

Presentations

Presentations

PRESENTATIONS

Date Title Documents

Corporate Presentation – March 2021

"Switching from agalsidase alfa to pegunigalsidase alfa to treat patients with Fabry disease: 1 year of treatment data from BRIDGE, a phase 3 open-label study," Presentation by Dr. Ales Linhart

"Switching from agalsidase alfa to pegunigalsidase alfa to treat patients with Fabry disease: 1 year of treatment data from BRIDGE, a phase 3 open-label study," Poster Presentation by Dr. Ales Linhart

“Pegunigalsidase alfa, a novel PEGylated ERT, evaluated in Fabry patients with progressing kidney disease, RCT study design,” poster presentation by Dr. David G. Warnock

“Pegunigalsidase alfa, a novel PEGylated ERT, evaluated in Fabry patients with progressing kidney disease, RCT study design,” oral presentation by Dr. David G. Warnock

“Pegunigalsidase alfa, PEGylated α-Galactosidase-A enzyme in development for the treatment of Fabry disease, shows correlation between renal Gb3 inclusion clearance and reduction of plasma Lyso-Gb3,” poster presentation by Prof. Derralynn Hughes

“Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study,” poster presentation by Dr. Ales Linhart

“Once every 4 weeks - 2 mg/kg of pegunigalsidase alfa for treating Fabry disease; Preliminary results of a Phase 3 study” -- Oral Presentation by Mr. Myrl D. Holida, PA, at the 15th Annual WORLDSymposiumTM 2019

Analysis of the baseline characteristics of Fabry disease patients screened for the pegunigalsidase alfa phase III BALANCE study” -- Poster Presentation by Prof. David Warnock at the 15th Annual WORLDSymposiumTM 2019

“Once every 4 weeks – 2 mg/kg of pegunigalsidase alfa for treating Fabry disease; Preliminary results of a phase 3 study” -- Poster Presentation by Mr. Myrl D. Holida, PA, at the 15th Annual WORLDSymposiumTM 2019

"Pegunigalsidase alfa for the Treatment of Fabry Disease - Phase III Open Label, Switch-Over Study from agalsidase alfa – Preliminary Results" -- Poster Presentation by Prof. Ales Linhart at the 15th Annual WORLDSymposiumTM 2019

"Pegunigalsidase alfa -- Novel Enzyme Replacement Therapy for the Treatment of Patients with Fabry Disease: Preliminary Results from the Phase III Bridge Study" - Presentation by Dr. Michael L. West at the 1st Canadian Symposium on Lysosomal Diseases 2018

"Pegunigalsidase alfa -- Novel Enzyme Replacement Therapy for the Treatment of Patients with Fabry Disease: Preliminary Results from the Phase III Bridge Study" - Presentation by Dr. Michael L. West at the 1st Canadian Symposium on Lysosomal Diseases 2018

"Novel Orally Administered Recombinant Anti-TNF alpha Fusion Protein for the Treatment of Ulcerative Colitis: Phase 2a Clinical Trial Showing Promising Results" -- Presentation by Dr. Yaron Ilan at the Digestive Disease Week® (DDW) 2018 Annual Meeting